UC Davis researchers shed new light on how chemotherapy-induced leukemia developsNovember 16, 2005Potentially fatal side-effect may be preventable, new study suggests (SACRAMENTO, Calif.) - Topoisomerase II inhibitors are among the most successful chemotherapy drugs used to treat human cancer. But a small percentage of patients treated with these agents recover from their initial malignancy only to develop a second cancer, leukemia. Researchers at UC Davis Cancer Center have shed new light on this poorly understood process. In a study to be published in the Nov. 22 issue of the journal Leukemia, the researchers report that topoisomerase II inhibitors do not directly cause leukemia - and suggest that it may be possible to prevent therapy-induced leukemia. (The study was posted online in the journal on Sept. 29.) "There are two competing theories of how these therapy-induced leukemias arise," said Andrew Vaughan, a radiation biologist at UC Davis Cancer Center and senior author of the new study. "One is that the topoisomerase II inhibitor drugs, in combination with the topoisomerase II enzyme they target, induce random genetic changes that lead to leukemia onset. The other is that another, potentially correctable process is at work." In the study, Vaughan and his colleagues at Loyola University and the Sacramento Veterans Administration Hospital linked what appears to be the earliest molecular event involved in the development of therapy-induced leukemia, the rearrangement of the MLL gene (a gene involved in leukemia), to factors that activate apoptosis, or programmed cell death. "This rearrangement appears to be independent of the topoisomerase II enzyme," Vaughan said. "This suggests that another process, such as apoptosis itself, is involved." Topoisomerase II inhibitors work by goading cancerous cells into apoptosis. Vaughan suggests that therapy-induced leukemia may occur when some cancer cells fail to complete apoptosis and instead survive in a mutated form that contains the leukemia-inducing MLL gene. "The good news is that apoptosis is a well-understood and potentially correctable process," Vaughan said. "Through genetic or pharmacologic means, we may be able to manipulate the cells that survive chemotherapy to complete apoptosis and die - averting the development of leukemia." University of California, Davis-Health System |
|||||||||||||||||||||
| Related Leukemia Current Events and Leukemia News Articles Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene. New research into the mechanisms of gene regulation A team led by Penn State's Ross Hardison, T. Ming Chu Professor of Biochemistry and Molecular Biology, has taken a large step toward unraveling how regulatory proteins control the production of gene products during development and growth. UAB Researchers Discover Antibody Receptor Identity, Propose Renaming Immune-System Gene Researchers at the University of Alabama at Birmingham (UAB) have uncovered the genetic identity of a cellular receptor for the immune system's first-response antibody, a discovery that sheds new light on infection control and immune disorders. U of M researchers find 2 units of umbilical cord blood reduce risk of leukemia recurrence A new study from the Masonic Cancer Center, University of Minnesota shows that patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning. Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor This research validates the potential for Stapled Peptides to modulate key intracellular biological targets, such as transcription factors, that have not been addressable with current small molecule or biologic drug modalities. Researchers 'notch' a victory toward new kind of cancer drug Scientists have devised an innovative way to disarm a key protein considered to be "undruggable," meaning that all previous efforts to develop a drug against it have failed. FDA approved leukemia drugs shows promise in ovarian cancer cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. First use of antibody and stem cell transplantation to successfully treat advanced leukemia For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options. American Dietetic Association Releases Updated Position Paper Promoting and Supporting Breastfeeding The American Dietetic Association has released an updated position paper on breastfeeding that details health benefits for both infants and mothers and encourages promotion of breastfeeding whenever possible. Drug shows promise in treating dangerous complication of erectile disorder Thousands of men are afflicted with an embarrassing and painful condition that triggers spontaneous, long-lasting erections. There are limited treatment options, but a solution could be on the way thanks to new research at The University of Texas Health Science Center at Houston. More Leukemia Current Events and Leukemia News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||